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Abstract
Improving the efficiency of treatment of locally distributed forms of breast cancer (BC) patients is relevant. 
The aim of the study: to determine the possibility of increasing the efficiency of treatment of patients with locally distributed 
BC by supplementing it with the determination of the expression of TOP2 alpha and beta-tubulin III genes in the primary tumor during 
various chemotherapy regimens. 
Method. 139 patients with locally distributed BC were examined. Patients received 2–4 courses of neoadjuvant chemotherapy 
(NAChT) according to the TC (docetaxel + cyclophosphamide) and TAC (docetaxel + doxorubicin + cyclophosphamide) regimens, 
subsequent surgical intervention and 2–4 courses of AchT according to the FAC regimen. Immunohistochemical (IHCh) study of the 
levels of estrogen receptors (ER), progesterone (PR), epidermal growth factor (HER2) in tumors was conducted. The expression of 
TOP2 alpha and beta-tubulin class III genes was determined using PCR. Statistical data processing was performed using the program 
Stastistica for Windows 6. 0, Excel.
Results. In the third cycle of chemotherapy, patients were transferred from the TC scheme to the TAC scheme. The frequency 
of the FPR increased 4 times in the group of patients with a triple negative tumor subtype compared with patients with luminal B. 
A combination of low expression of the class III beta-tubulin gene with high expression of TOP2 alpha in tumor tissue was found in 
64.5 % of patients treated according to the TAC + cross over regimen and in 56.3 % of cases according to the TC regimen. A change 
in the receptor status of MLN after NAChT was detected in some cases.
Conclusions. The combination of high expression of TOP2 alpha with low expression of class III beta-tubulins can be consid-
ered as a predictive sign of full pathomorphological response when using taxane-containing locally distributed BC. These markers can 
be recommended for determination in MLN (along with definition of ER, PR, HER2) in order to increase the effectiveness of AchT.
Keywords: locally distributed breast cancer, chemotherapy, estrogen, progesterone receptors, HER2, lymph nodes, topoisom-
erase II alpha, beta-tubulin III.
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1. Introduction
Breast cancer (BC) among the oncological pathologies in women by incidence in recent 
years has come first in the world. More than 400 thousand women die from this disease [1]. In 
Ukraine, according to data of Cancer-Register of 2016–2017, [2], the incidence of breast cancer 
was 74.4, mortality 30.2 per 100 thousand of the population. The average age of 80 % of patients 
is 61 years old, and about 20 % of patients are less than 50 years old (these include 30-year-old and 
40-year-old women). The high incidence of breast cancer and mortality from this pathology, the 
high recurrence rate after standard treatment requires further study of ways to increase the effi-
ciency of treatment for breast cancer and makes this issue relevant.
Current recommendations for the treatment of BC are based on an understanding of its bio-
logical heterogeneity, which determines the need to isolate molecular biological types for adequate 
individualized therapy. Based on the immunohistochemical (IHCh) analysis of estrogen recep-
tors (ER) and progesterone (PR), epidermal growth factor receptor 2 (HER2), some cytokeratins, 
the expression level of the Ki-67 proliferation marker, a breast cancer classification was created, 
Original Research Article:
full paper
(2020), «EUREKA: Health Sciences»
Number 3
7
Medicine and Dentistry
according to which BC variants differ in prognosis and sensitivity to various types of drug thera- 
py [1, 3]. The frequency of detection of various molecular types of BC, determined on the basis 
of IHCh evaluation of the expression of ER, PR and HER2/neu, is not the same. Moreover, lumi-
nal types are associated with a less aggressive course and a good prognosis in comparison with 
HER2 + and basal-like types [4]. The presence of estrogen and progesterone receptors in a breast 
tumor correlates with a good prognosis of relapse-free and overall patient survival [5]. The results 
of IHCh studies of BC have opened up prospects for the use of modern methods of complex and 
combined treatment, the use of targeted drugs. 
Based on immunohistochemical (IHC) analysis of estrogen and progesterone receptors, epi-
dermal growth factor receptor HER2, some cytokeratins, the expression level of the Ki-67 prolif-
eration marker, a breast cancer classification was created, according to which antibodies of breast 
cancer differ in prognosis and sensitivity to various types of drug therapy [1, 3].
The frequency of detection of various molecular types of BC, determined on the basis of IHCh 
evaluation of the expression of ER, PR and HER2/neu, is not the same. Moreover, luminal types 
are associated with a less aggressive course and a good prognosis in comparison with HER2 + and 
basal-like types [4]. The presence of estrogen and progesterone receptors in a breast tumor correlates 
with a good prognosis of relapse-free and overall patient survival [5]. The results of IHCh studies of 
BC have opened up prospects for the use of modern methods of complex and combined treatment, the 
use of targeted drugs. At the same time, the issues of hormonal activity of metastatic lymph nodes, 
their production of various signal molecules (which can be especially informative with neoadjuvant 
therapy) have not been studied enough. It should be noted that certain recommendations regarding 
the need for immunomorphological studies of LN in the presence of metastases in them do not exist. 
Moreover, metastatic lesion of regional LN in BC is the most significant prognosis [6, 7]. Therefore, 
the issue of accurate and detailed diagnosis of regional metastases is of fundamental importance. To 
date, morphological and IHC studies can accurately diagnose metastases in regional LN in patients 
with breast cancer, however, such a combined approach is time-consuming, requires considerable 
time, and the result is not always objective.
Theoretically, the cellular elements of metastases are the most aggressive clone of tumor 
cells, and it is advisable to pay attention to them as potentially circulating in the body and being the 
target for adjuvant therapy, since the primary tumor has already been removed.
The use of neoadjuvant chemotherapy (NAChT) of locally distributed BC and its inflamma-
tory forms, the purpose of which is to transfer the tumor from inoperable to operable, reduce the 
stage of the disease, evaluate the pathological response, allows you to recognize the sensitivity to 
a particular drug at the preoperative stage [8, 9]. According to a large array of studies [10, 11], the 
primary tumor and micrometastases have similar sensitivity to ChT drugs.
Therefore, with the ineffectiveness of neoadjuvant systemic therapy, a similar response 
to treatment with the same drugs in the adjuvant mode can be predicted. However, according 
to [12] and based on our own studies [13], differences in the immunophenotype of cells in pri-
mary tumors and their metastases were revealed. The results of our previous IHCh and mor-
phological studies [13, 14] showed that in the process of conducting NAChT not only the loss 
of the corresponding receptors occurs, but also the transformation of cells with the appearance 
of new phenotypes. The appearance of new receptors (ER, HER-2) occurs much less frequently 
than the loss of the same receptors under the influence of neoadjuvant therapy (NAChT). The 
differences between the primary tumor and metastases in the LN can be explained from the 
standpoint of the theory of cancer stem cells (CSC) and epithelial-mesenchymal transforma- 
tion (EMT). The use of a comprehensive and combined treatment approaches, taking into ac-
count not only the morphobiological type of the primary tumor, but also regional lymph nodes, 
opens the way to individualizing treatment, reducing the number of relapses, and increasing the 
five-year relapse-free survival rates.
It is known, that modern NAChT is characterized by a number of drawbacks, including the 
empirical choice of its purpose, a decrease in the quality of life of patients, and a low therapeutic 
effect. Therefore, the rejection of deliberately ineffective treatment may be the best solution to 
the problem [15]. In this regard, it becomes appropriate to search for markers that can predict the 
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response to chemotherapy in advance, reduce the frequency of side effects, and reduce the cost of 
treatment due to the more reasonable use of drugs [16, 17].
Knowledge of the molecular genetic characteristics of not only the primary tumor, but also 
regional LN can individualize the choice of cytostatic and reduce the risk of side effects [18]. Among 
these characteristics described in the scientific literature are: topoisomerase II alpha (TOR2 alpha) 
(a complex protein necessary for DNA replication, the main target of doxorubicin, which inhibits 
TOR2 alpha), and beta-tubulin III protein (responsible for sensitivity to taxane formulations that 
stabilize its HDF-bound form). This leads to the blocking of depolymerization, stimulation of tu-
bulin polymerization due to the absence of GTP, stops the cell cycle and activates apoptosis. The 
data on the predictive and prognostic value of the expression of the TOP2 alpha and beta tubulin 
III genes for patients with locally distributed BC are contradictory [18, 19]. According to [20, 21], 
overexpression of this protein in tumors in the treatment of ovarian cancer (RV) and lung can- 
cer (RL) with paclitaxel is an unfavourable prognostic factor [22, 23].
In connection with the foregoing, the aim of this study was to determine the possibility of 
increasing the effectiveness of treatment of patients with locally distributed BC by supplementing 
it with the determination of the expression of topoisomerase II alpha (TOP2 alpha) and beta-tubulin 
III genes in the primary tumor during various chemotherapy regimens. To evaluate the possibility 
of determining these parameters in metastatic lymph nodes after cytoreductive surgery to individ-
ualize adjuvant chemotherapy.
2. Materials and Methods
139 patients with a diagnosis of breast cancer aged 29 to 64 years old, who were from 2014 
to 2018, were examined. They were undergoing treatment at the chemotherapy department of the 
Kharkiv Regional Clinical Oncology Center and the city clinical multidisciplinary hospital No. 17.
The criteria for inclusion of women in the survey group were: age over 18 years old, histo-
logically confirmed locally distributed BC (T1-2N2-3M0; T4N0-3M0); the presence of measurable 
foci of the tumor; known status of estrogen receptors (ER) and/or progesterone (PR), as well as epi-
dermal growth factor (HER2/neu); consent of the patient with breast cancer to receive a complex of 
examination and treatment. The exclusion criteria from the examination were: conducting therapy 
in other medical institutions; severe neurological pathology; the presence of another active oncopa-
thology; pregnancy; uncontrolled hypertension, a high degree of risk of uncontrolled arrhythmia; 
the following changes in laboratory parameters (creatinine>2.0 mg/dl; ALT, AST or serum biliru-
bin 2.5 times higher than normal (total serum bilirubin>27.34 μmol/l); hemoglobin <9 g/l; platelets 
less than 100000/μl; leukocytes less than 2.109/l mental illness, drug or alcohol addiction; lack of 
patient consent. 
The studies were carried out in accordance with the Declaration of Helsinki; the procedures 
were approved by the local ethics committee of Kharkiv medical academy of postgraduate edu-
cation, protocol No. 5, 12.11.2019. Informed consent for the participation was obtained from all 
the patients.
To determine the biological subtype of the tumor (luminal A; luminal B; three times neg-
ative HER2 +), ER and PR levels, HER2/neu expression, and the degree of histological malig-
nancy (G) were determined using the IHC method. Additionally, the amplification of the HER2 
gene was determined by the FISH method.
The complex treatment measures for the examined patients included: conducting 2–4 cours-
es of NAChT according to the TC (docetaxel + cyclophosphamide) and TAC (docetaxel + doxo-
rubicin + cyclophosphamide) regimens, subsequent surgery and 2–4 courses of adjuvant therapy 
according to the FAC scheme. Radiation or hormone therapy was prescribed according to indica-
tions. Every 2 cycles the clinical response using physical and instrumental methods were studied. 
When stabilization occurs after two cycles of NACT according to the TC regimen, patients were 
transferred to the TAC group. In this case, stabilization was considered as an insufficient response 
to the NACT.
The clinical evaluation of NAChT was carried out according to the following criteria: com-
plete disappearance of the primary tumor in the mammary gland and regional LN; reduction in the 
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size of the tumor by 50 % or more; stabilization – criteria insufficient to achieve partial regression; 
disease progression – an increase in tumor size by more than 25 %.
The degree of drug pathomorphosis was evaluated according to the classification by 
I. D. Miller, S. Payne (2002).
Monoclonal rabbit antibodies (MKAB) were used for IHC against estrogen receptors 
SP1 Spring Bio 1:250, against progesterone receptors SP2 Spring Bio 1:350, against HER2/neu 
V9 Roche/Ventana rtu. 1:100. To determine the expression of topoisomerase II-alpha and beta- 
tubulin class III genes, real-time PCR was used using Taq Man-samples using a BioRad CFX96 
Real time PCR detection System (USA). Expression indices of less than 20 percentiles were cate-
gorized as “low”, and more than 80 percentiles were “high”.
Statistical processing of the obtained data was carried out using the program Stastistica for 
Windows 6. 0, statistical package R and the spreadsheet processor Excel. Differences were consid-
ered significant at p<0.05.
3. Results
Comparison of treatment results for locally distributed BC patients according to TAC and 
TC schemes showed the advantage of the first of the listed options (i. e. TAC). At the same time, 
there were no significant differences between taxane-containing chemotherapy with the addition 
of anthracyclines and without them with a complete pathomorphological response (T0N0) due to 
the fact that in the third cycle of PCT, patients were transferred from the TC scheme to the TAC 
scheme, since the stabilization found in them was regarded as insufficient answer.
Studies have shown that the frequency of the full pathomorphological response increased 
4 times in the group of patients with a triple negative tumor subtype compared with BC patients 
with luminal B. Moreover, with luminal A it was 8.5 % (confidence interval (CI 2.7–17.0), with 
luminal B – 6.7 % (CI 0.5–18.8), with HER2 + 23.8 % (CI 7.7–45.3), with a triple negative sub- 
type – 25.8 % (CI 11.7–43.1).
A significant pathomorphological response was observed in 11 patients with luminal A 
subtype (4+5 tbsp. According to Miller-Raul), which amounted to 8.6 % (CI 9.7–29.7); in 5 patients 
with a luminal B subtype (16.7 % CI 5.4–32.6); in 9 patients with HER2 + type 42.9 % (CI 21.8–
65.4); in 12 patients in the group of thrice negative subtype of breast cancer, 38.7 % (CI 22.0–57.0).
In patients with HER2 + and thrice-negative breast cancer, when anthracycline or taxane 
was included in ChT, a higher incidence of CDPT (complete disappearance of the primary tumor) 
and a significant pathomorphological tumor response (4+5 st. according to Miller-Raul) were ob-
served compared with the luminal subtypes A and B. It should be noted that complete disappear-
ance of the primary tumor and a significant pathomorphological response were considered by us in 
each group as criteria for the effectiveness of taxane-containing chemotherapy.
The determination of beta-tubulin III expression in the tumor showed low results in 34 pa- 
tients (58.6 %) and high results in 24 (41.4 %) patients. In the group of patients with low expression 
of class III beta-tubulin in the tumor, a significant pathomorphological response was achieved 
in 18 (23.1 %) women, a significant degree of pathomorphological response was achieved in 
16 patients (39.7 %). At the same time, in the group of patients with low expression of class III 
beta-tubulin, CDPT was observed in 18 cases (23.1 %), and in the group with their high expres-
sion, only in one patient (p<0.001).
In the group of patients with low expression of class III beta-tubulin who received che-
motherapy according to the TAC+ cross over (TC-TAC) regimen, CDPT was observed in 10 pa- 
tients (20.8 %), and in the group with high expression, in one patient (2.4 %) (0.0–9.6) at p<0.005.
In patients with low expression of beta-tubulin III who received chemotherapy according to 
the TS regimen, a significant pathomorphological response was detected in 8 cases (26.7 %) (CI 12.1–
44.4), and in the group with high expression, only in 1 patient (p<0.005). The obtained results allow 
us to state that low expression of the class III beta-tubulin gene in tumor tissue in breast cancer is a 
reliable predictive sign of the achievement of MTCT in response to taxane-containing chemotherapy.
The predictive value of topoisomerase II-alpha as a marker of tumor sensitivity to anth-
racycline antibiotics was also studied in a group of patients who received chemotherapy with 
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TAC + cross over. In patients with breast cancer with low gene expression of topoisomerase 
II-alpha in response to NACT with the inclusion of anthracycline antibiotics, a significant pathomo-
rphological response was observed in 1 patient (1.6 %), and in the group with high expression, in 
18 (24.7 %) (p<0.001). In the group of patients with high expression of topoisomerase, the II-alpha 
pathomorphological response was achieved in 33 (45.2 %) women (33.8–56.8) with p<0.001.
When establishing high expression of topoisomerase II-alpha in combination with low 
expression of class III beta-tubulin, a significant pathomorphological response in the group 
of breast cancer patients treated according to the TAC + cross over scheme was achieved in 
20 cases (64.5 %), in the group of patients treated according to the TC-scheme in 9 women (56.3 %) 
(30.0–80.7) at p=0.58.
The combination of high expression of topoisomerase II-alpha and low expression of class 
III beta-tubulin in relation to CDPT showed that in the group of patients who received NAChT 
according to the TAC + cross over scheme, the 5th degree of pathomorphological response was 
achieved in 10 cases (32.3 %) (16.7–50.2), and according to the TC scheme, in 7 cases (43.8 %) 
(19.3–70.0).
Thus, the combination of high expression of topoisomerase II-alpha with low expression 
of class III beta-tubulin can be considered as a predictive sign of achieving CDPT when using 
taxane-containing chemotherapy. Therefore, the molecular markers mentioned above should be 
included in the diagnostic complex for evaluating the efficacy of NAChT in patients with locally 
distributed BC and can be recommended for determination in LN (along with ER, PR, HER2) after 
cytoreductive surgery to plan effective AChT.
4. Discussion
Discussing the results with the data of scientific literature, we can conclude that one of the 
main problems of tumor resistance in locally distributed BC to therapy is the change in its biology 
during progression or under the influence of the therapy [13, 14]. During the implementation of the 
metastatic cascade, cancer cells, losing a set of epithelial antigens and acquiring a set of mesenchy-
mal (epithelial-mesenchymal transformation-EMT), can change their initial phenotype (for exam-
ple, lose steroid hormonal receptors or epidermal growth factor receptors) [24]. This explains the 
fact of different chemosensitivity of the primary tumor and its lymphogenous metastases, which 
must be taken into account when conducting adjuvant treatment. Individualization of antitumor 
therapy involves treatment not only taking into account the molecular status of the primary tumor, 
but also taking into account the phenotype of the cells of its metastases [19].
It should be noted that in some cases, the use of approaches to increase the efficiency of 
the treatment of hormone-dependent tumors of other locations, for example, locally distributed 
ovarian cancer, may become promising for solving the same problem with respect to breast can-
cer. Thus, according to [25], frequent relapses of the disease after treatment and a high mortality 
rate in patients with stage III–IV ovaries worldwide can be explained from the standpoint of the 
theory of tumor stem cells based on the study of prognostic tumor markers, which allows us to 
adjust the treatment strategy. The results of the determination of Ki-67 made it possible to sup-
plement the clinical signs of the efficiency of NAChT in OC III-IV stages, indicating a decrease 
in this indicator in the tumor after NAChT by almost 4 times, which was accompanied by a 
decrease in CA125. In patients with a locally advanced tumor process, an opportunity arose for 
cytoreductive surgery.
At the same time, an increase in the expression of bcl-2, a decrease in the expression of cy-
tokeratin-7 in 37 % of patients and E-cadherin in tumors after NAChT is a sign of a poor prognosis 
of the further course of OC, which can be explained from the perspective of the theory of CSC, 
responsible for maintaining oncogenesis and heterogeneity tumors. The rupture of intercellular 
bonds in accordance with a decrease in the expression of E-cadherin can be one of the factors 
of epithelial-mesenchymal transformation (EMT), cell de-differentiation, acquisition of an CSC 
phenotype by a tumor cell, and transition of cells to a mesenchymal phenotype. Such cells have an 
aggressive malignant potential that affects survival. At the same time, a high degree of expression 
of cytokeratin-7 in 63 % of patients with OC of III–IV art. gives hope for the differentiation of 
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tumor cells. Despite the effectiveness of the influence of NPHT on the treatment of late stage OC, 
the threat of relapse of the OC due to the formation of CSC and the threat of EMT remains in the 
patient’s body. A promising approach to the development of new methods for the treatment of late 
stage ovaries can be the prevention of EMT and, in particular, the loss of E-cadherin.
The question of creating a complex of quantitative diagnostic criteria for the efficiency of 
NAChT and AHT, criteria for evaluating EMT, and prognosis of the course of locally distributed 
BC is being discussed.
Study limitations. Thus, the solution to the problem of increasing the efficiency of treat-
ment for BC is not limited to determining the expression of TOP2 alpha and beta-tubulin III genes 
in the primary tumor during various chemotherapy regimens and metastatic LN to individualize 
adjuvant chemotherapy and has prospects. 
Prospects for further research. Prospects for further research: promising continuation of 
research may be the determination of tumor markers of epithelial-mesenchymal transformation in 
a tumor. Such studies will help to identify patients with breast cancer with a poor prognosis and to 
develop ways to prevent epithelial-mesenchymal transformation. 
5. Conclusion
The receptor status of metastatic lymph nodes in patients having locally distributed BC 
may change under the influence of chemotherapy and may differ from the receptor status of the 
primary tumor.
The combination of high expression of topoisomerase II-alpha with low expression of class 
III beta-tubulin can be considered as a predictive sign of the achievement of full pathomorphological 
response when using taxane-containing chemotherapy in patients having locally distributed BC.
One of the ways to increase the treatment efficiency of locally distributed BC can be consid-
ered not only the determination of the expression of topoisomerase II alpha and beta-tubulin class 
III in the primary tumor and metastatic LN, along with the determination of ER, PR, HER2, which 
allows to increase the efficiency of NAChT and AHT.
The determination of molecular markers characterizing epithelial-mesenchymal transfor-
mation in a tumor is a promising approach to increasing the effectiveness of the treatment of locally 
distributed BC due to inhibition or prevention of this process.
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